
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is a leading biotechnology company in the emerging field of psychedelic medicine, with a strong focus on developing treatments for mental health disorders. Their pioneering approach, using a proprietary synthetic psilocybin formulation alongside psychological support, has shown promising results in multiple clinical trials for treatment-resistant depression. With Breakthrough Therapy designation from the FDA and ongoing clinical trials for other indications, the company is well-positioned to be a leader in the psychedelic therapeutics space. We see room for multiple winners in this emerging class and believe CMPS has a strong potential for revenue growth, particularly in the treatment-resistant depression market. The company's strong financials and pipeline of other potential indications such as PTSD and anorexia nervosa also contribute to our positive outlook.
Bears say
Compass Pathways is valued at $21 per share, based on a DCF analysis of its current drug development and potential market success. The company's risk-adjusted COMP360 revenues in the treatment-resistant depression market and modest credit for its PTSD program contribute to its valuation. However, the potential for regulatory and IP exclusivity issues, as well as challenges in defining reimbursement pathways, could negatively impact the company's future success and result in a decline in stock value.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares